# Action Potential Venture Capital

> Action Potential Venture Capital is a VC fund backing Medical and Health Care. See 34 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 34
- Last investment: Aug 2025
- Lead investor: 15%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/9130275?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A9130275%2Cidx%3A1-1-1%2CtarId%3A1441824670372%2Ctas%3AAction%20Potential%20Venture%20Capital
- Website: http://www.actionpotentialvc.com/

Action Potential Venture Capital is a VC fund in Cambridge focused on Medical and Health Care. GlaxoSmithKline today announced the launch of Action Potential Venture Capital (APVC) Limited, a new $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies. The fund’s first investment will be in SetPoint Medical, a California company considered a trailblazer in creatingimplantable devices to treat inflammatory diseases.The fund complements the work of GSK’s Bioelectronics R&D unit, which was established in 2012 after a two-year effort to seek out and engage the most promising researchers in this emerging area of science. The name of the fund comes from electrical signals called action potentials that pass along the nerves in the body. Irregular or altered patterns of these impulses may occur in association with a broad range of diseases. GSK believes that miniaturised devices, or bioelectronic medicines, can be designed to read these patterns. The devices could be designed to interface between the peripheral nervous system and specific organs to read, change or generate electronic impulses that help treat disorders as diverse as inflammatory bowel disease or rheumatoid arthritis; respiratory diseases such as asthma and COPD and metabolic diseases including Type 2 diabetes.The field of bioelectronic medicines is in its very early stages. GSK’s ambition, through collaboration with scientists globally, is to have the first medicine that speaks the electrical language of our body ready for approval by the end of this decade.“We want to help create the medicines of the future and be the catalyst for this work,” said Moncef Slaoui, chairman of R&D and architect of GSK’s early stage investment strategy. “GSK can play the integrating role that is needed to drive this new type of medical treatment all the way from the bench to the patient and this fund is a key part of our efforts.”Action Potential Venture Capital intends to build a portfolio of five to seven companies over the next five years. The fund will focus investments in three areas:- New start-up companies that aim to pursue the vision of bioelectronic medicines- Existing companies with technologies that are interacting with the peripheral nervous system through first-generation devices that can stimulate or block electrical impulses- Companies advancing technology platforms that will underpin these treatment modalitiesAction Potential Venture Capital will be based in Cambridge, Massachusetts and managed by a small, dedicated team. The fund has named Imran Eba as its first partner. Imran will move from GSK’s Worldwide Business Development organisation and work closely with the Bioelectronics R&D unit.

## Contacts

5 contacts available for Action Potential Venture Capital. Shizune tracks 4 team members at Action Potential Venture Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/action-potential-venture-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 8 | 24% |
| Health Care | 7 | 21% |
| Medical Device | 6 | 18% |
| Biotechnology | 4 | 12% |
| Health Diagnostics | 3 | 9% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 18% |
| Series A | 4 | 12% |
| Series C | 4 | 12% |
| Series D | 3 | 9% |
| Funding Round | 2 | 6% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 29% |
| Australia | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ali Kight | Summer Associate | 0 | https://shizune.co/investors/profile/ali-kight-c7ac |
| Isaac Stoner | Summer Associate | 0 | https://shizune.co/investors/profile/isaac-b-stoner |
| Jens Eckstein | Director and Managing Partner | 18 | https://shizune.co/investors/profile/jens-eckstein |
| Juan-Pablo Mas | Partner | 19 | https://shizune.co/investors/profile/juan-pablo-mas |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $115M | Series D | Aug 11, 2025 |  |
| Alpheus Medical | Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM). | $52M | Series B | May 15, 2025 |  |
| Mobia Medical | MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and variousneurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues.Founded in 2007, MicroTransponder is headquartered in Dallas, Texas. | $65M | Series F | Mar 12, 2025 |  |
| Saluda Medical | Saluda Medical was established in 2013 with the goal of commercializing four years of research from NICTA, Australia’s information communications technology center of excellence.Our team is made up of world-class engineers, clinicians and seasoned professionals with experience in bringing medical technologies to life.Our company is founded on astrong foundation of science and we are dedicated to developing breakthrough | $100M | Venture - Series Unknown | Jan 10, 2025 |  |
| Cala Health | Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. |  |  | Dec 09, 2024 |  |
| Cala Health | Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. | $50M | Series C | Dec 09, 2024 |  |
| NeuSpera Medical | NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeperand more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain | $23M | Series D | Jul 15, 2024 |  |
| Presidio Medical | Presidio Medical is a medtech company that develops a transformational neuromodulation platform. It enables people to receive remedies for disorders affecting neuronal activity. | $72M | Series C | Jun 26, 2023 |  |
| Saluda Medical | Saluda Medical was established in 2013 with the goal of commercializing four years of research from NICTA, Australia’s information communications technology center of excellence.Our team is made up of world-class engineers, clinicians and seasoned professionals with experience in bringing medical technologies to life.Our company is founded on astrong foundation of science and we are dedicated to developing breakthrough | $150M | Venture - Series Unknown | Apr 13, 2023 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $80M |  | Jan 19, 2023 |  |

10 of 34 investments shown.

## Co-investors
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 9 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 9 deals together
- [Boston Scientific](https://shizune.co/investors/profile/boston-scientific) — VC Fund, 6 deals together
- [Shangbay Capital](https://shizune.co/investors/profile/shangbay-capital) — VC Fund, 6 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 5 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Action Potential Venture Capital invest in?

Action Potential Venture Capital invests primarily in Medical, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 34 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Action Potential Venture Capital?

Public channels for Action Potential Venture Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Action Potential Venture Capital?

The team at Action Potential Venture Capital includes Ali Kight (Summer Associate), Isaac Stoner (Summer Associate) and Jens Eckstein (Director and Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co